Loading…
Based on limited metadata, American Preclinical Services received an FDA Warning Letter on February 12, 2019, regarding biologics products or services. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning pertains to biologics, a highly regulated category under FDA oversight, though the specific issuing office is not identified in the metadata provided. A complete review of the actual Warning Letter would be necessary to identify the specific compliance issues cited.